Serum Talin-1 and Cripto-1 in Colorectal Cancer (Talin-1/CR-1)

Evaluating Serum Talin-1 and Cripto-1 as Diagnostic Biomarkers in Colorectal Cancer

The goals of this study are

• To evaluate the clinical utility of Talin-1 and Cripto-1 measurement in colorectal cancer patients in comparison with healthy controls.
• To Compare the diagnostic significance of serum Talin-1 and Cripto-1 with traditional serum biomarker CEA

Study Overview

• Status: Not yet recruiting
• Conditions: Colo-rectal Cancer
• Intervention / Treatment: Diagnostic test: Serum level of Human Talin-1; Diagnostic test: Serum level of Human Cripto-1

Detailed Description

Colorectal cancer (CRC) is a major global health concern, ranking as the third most commonly diagnosed cancer and the second leading cause of cancer-related deaths. CRC is a malignancy predominantly affecting older adults, posing significant threats to their health and creating formidable challenges for healthcare systems.

Compared to younger patients, elderly CRC often presents with atypical symptoms. In some cases, the initial manifestations are not hematochezia or abdominal pain but anaemia and weight loss, leading to frequent late-stage (Stage IV) diagnoses, which complicates treatment.

Talin-1 serves as a crucial element within the multiprotein adhesion complexes that facilitate processes such as cell migration, adhesion, and integrin signalling. It has been demonstrated that the level of Talin-1 in the serum of colon cancer patients was significantly higher than that of healthy controls. Talin-1 may be a valuable biomarker for colon cancer, which may be essential for the early detection, especially in combination with other markers in population screenings that are currently used to detect the colon cancer.

Human Cripto-1 (CR-1) is an embryonic gene, belonging to the EGF-CFC gene family, which is necessary for promoting early stages of embryonic development. CR-1 is a good example of a multifaceted embryonic protein that is re-expressed in most human tumors, particularly colorectal tumor, but not detected in normal adult human tissues. García-Sanmartín et al. showed that Cripto-1 expression was significantly correlated with worse prognosis in CRC, and was an independent prognostic factor.

• Study Type: Interventional
• Enrollment (Estimated): 70
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Sherouk Ahmed Sayed, Assistant lecturer; Phone Number: +201009922949 +201123232632; Email: shrookabozaid@gmail.com

Study Locations

• Egypt
  • Asyut Governorate
    • Asyut, Asyut Governorate, Egypt, 17777
      • Assuit University Hospital
      • Contact: Sherouk Ahmed; Phone Number: 01123232632

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Age >18 years Old.
• Patients of both sexes who met the clinical diagnostic criteria of colorectal cancer (change in bowel habit, absolute or recurrent constipation, rectal bleeding, significant weight loss or intestinal obstruction)
• Patients diagnosed with colorectal cancer by imaging and histopathology

Exclusion Criteria:

• Age <18 years old.
• Patients with past history of chemotherapy or surgical excision of tumor
• Patients with familial adenomatous polyposis
• Patients with hereditary non-polyposis colorectal cancer
• Patients with inflammatory bowel disease
• patients with other types of tumors

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group(1)	Diagnostic test: Serum level of Human Talin-1; To evaluate the clinical utility of Talin-1 measurement in colorectal cancer patients in comparison with healthy controls.; Diagnostic test: Serum level of Human Cripto-1; To evaluate the clinical utility of Cripto-1 measurement in colorectal cancer patients in comparison with healthy controls.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Serum Talin-1 measurement in colorectal cancer patients	measuring serum level of talin-1 in colorectal cancer patient to compare its level with healthy control	From enrollment up to one week

Secondary Outcome Measures

Outcome Measure	Time Frame
Serum Cripto-1 measurement in colorectal cancer patients	From enrollment up to one week

Collaborators and Investigators

• Sponsor: Assiut University

Study record dates

Study Major Dates

• Study Start (Estimated): March 30, 2026
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2029

Study Registration Dates

• First Submitted: January 24, 2026
• First Submitted That Met QC Criteria: February 12, 2026
• First Posted (Actual): February 17, 2026

Study Record Updates

• Last Update Posted (Actual): February 17, 2026
• Last Update Submitted That Met QC Criteria: February 12, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Intestinal Diseases; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colorectal Neoplasms; Intestinal Neoplasms; Colonic Diseases; Colonic Neoplasms
• Other Study ID Numbers: SHROOK

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No